Lonza Inc. and BioWa Sign License Agreements with FivePrime Therapeutics, Inc. for Use of Their POTELLIGENT® CHOK1SV Cell Line for Therapeutic Antibody Development
6/13/2012 10:25:54 AM
More...
|
FivePrime Therapeutics, Inc. Announces That Human Genome Sciences Files U.S. IND for HGS1036/FP-1039 FGF Ligand Trap
6/4/2012 10:02:38 AM
More...
|
FivePrime Therapeutics, Inc. Announces the Promotion of Aron Knickerbocker to Senior Vice President and Chief Business Officer
5/3/2012 9:42:41 AM
More...
|
FivePrime Therapeutics, Inc. Inks Second Strategic Alliance With GlaxoSmithKline (GSK) in Deal Worth $223.5 Million
4/17/2012 9:37:02 AM
More...
|
FivePrime Therapeutics, Inc. Confirms Appointment of Lewis T. "Rusty" Williams as CEO and Announces the Appointment of Brian Atwood as Chairman of the Board
2/6/2012 3:07:12 PM
More...
|
FivePrime Therapeutics, Inc. Elects Peder Jensen, M.D. to Its Board of Directors
9/15/2011 10:00:18 AM
More...
|
FivePrime Therapeutics, Inc. CEO Done After Two Years, Rusty Williams Takes Over
8/18/2011 6:56:25 AM
More...
|
FivePrime Therapeutics, Inc. Provides an Update on Its Strategic Discovery Collaborations With Pfizer and GlaxoSmithKline (GSK)
6/16/2011 10:42:30 AM
More...
|
Dyax Corp. (DYAX) and FivePrime Therapeutics, Inc. Enter Into Research Agreement for Discovery of Therapeutic Antibodies
4/27/2011 10:53:03 AM
More...
|
FivePrime Therapeutics, Inc. to Present at Future Leaders in the Biotech Industry Conference in New York
4/7/2011 9:18:57 AM
More...
|
|